Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 4 study of tacrolimus ointment 0.03% in infants and toddlers with atopic dermatitis
jRCT2031230181Phase 4Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Oct 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in atopic dermatitis (AD), sponsored by Maruho Co., Ltd. Primary endpoint: EASI. Started Oct 2023; status: completed.
02
Drugs
tacrolimus
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230181.